Epidemiology and Clinical Features of Cutaneous Leishmaniasis in Badrood City, Iran, in 2013

Document Type : Original Article (s)

Authors

1 Associate Professor, Social Determinants of Health (SDH) Research Center, Kashan University of Medical Sciences, Kashan, Iran

2 Associate Professor, Department of Infectious Diseases, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

3 Pediatrician, Isfahan University of Medical Sciences, Isfahan AND Badrood Hospital, Badrood, Iran

4 Nurse, Kashan University of Medical Sciences, Kashan, Iran

Abstract

Background: Cutaneous Leishmaniasis (CL) is a common endemic parasitic disease in Iran. This disease is always a serious health problem in Isfahan province, especially in Badrood city, and its prevalence has been doubled over the last decade. This study was designed to determine the epidemiology and clinical features of cutaneous leishmaniasis in Badrood city in 2013.Methods: This descriptive cross-sectional study was done on all detected patients with cutaneous leishmaniasis in Badrood city via active detection during one year. Patients were visited by physician and a questionnaire including the demographic data and characteristics of the wounds were filled through interview and examination of patients. Diagnosis was confirmed via revealing of the leishman body in smear of the wounds. The results were analyzed using SPSS software.Findings: 55.6% of the patients were men. Age group of 15-30 years had the highest rate (23.8%) among the patients. 66.7% of patients had history of staying in Agha Ali Abbas region. All the wounds were of the rural form. The lesions of cutaneous leishmaniasis were painless, pruritus, less than 3 cm, and with secretion. Extremities were the most common sites for the infection. There was complete or partial healing after the treatment in most of the patients.Conclusion: Based on the findings of this study, cutaneous leishmaniasis in Badrood city is rural form and most of the patient are men and older than 15 years of age. Complete or partial healing can be seen after the treatment in most of the patients.

Keywords

References

  1. Service M. Medical Entomology for Students. Cambridge, UK: Cambridge University Press; 1996. p. 95-103.
  2. World Health Organization. Scientific working group on Leishmaniasis [Online]. [cited 2004 Feb 2-4]; Available from: URL: http://www.who.int/tdr/publications/tdr-research-publications/swg-report-leishmaniasis/en/
  3. Piscopo TV, Mallia AC. Leishmaniasis. Postgrad Med J 2007; 83(976): 649-57.
  4. Azadeh B, Ardehali S, Javadian E, Seiedi A, Saberi MS, Sadeghi E, et al. Leishmania and leishmaniasis. Tehran, Iran: Iran University Press; 1994. [In Persian].
  5. World Health Organization. Leishmaniasis. Geneva, Switzerland: World Health Organization; 1989.
  6. Mohebali M, Yaghoobi P, Hooshmand B, Khamesipour A. Efficacy of Paromomycin ointment prepared in Iran (Paromo-U) against cutaneous Leishmaniasis caused by Leishmania major in mouse model. Iran J Dermatol 2004; 7(26): 88-94. [In Persian].
  7. Mohebali M. Zoonotic protozoa diseases. Tehran, Iran: Nadi Publication; 1996. p. 60. [In Persian].
  8. Nadim A, Javadian AE, Tahvildari Gh. Leishmanisation and its usage on cutaneous leishmaniasis control. Proceedings of the 1st Seminar on Leishmaniasis Survey in Iran. Tehran, Iran: Imam Hossein University; 1992; p. 46. [In Persian].
  9. World Health Organization. Control of the leishmaniases. Geneva, Switzerland: World Health Organization; 2010.
  10. World Health Organization. Control of tropical diseases: the leishmaniases. Geneva, Switzerland: World Health Organization; 1993.
  11. Shirzadi MR. National Programme of leishmaniasis. Proceedings of the 4th National Congress of diseases transmitted between animals and humans; 1996 Apr 23-26; Tehran, Iran; 1996.
  12. Doroudgar A, Mahboubi S, Nematian M, Sayah M, Doroudgar M. An epidemiological study of cutaneous leishmaniasis in Kashan (2007-2008). Koomesh 2009; 10(3): 177-83. [In Persian].
  13. Ramezani Y, Mousavi S, Bahrami A, Fereydooni M, Parsa N, Kazemi B. Epidemiological study of cutaneous leishmaniasis in Aran and Bidgol from April to September 2009. Feyz 2011; 15(3): 254-8. [In Persian].
  14. Saghafipour A, Akbari A, Rasi Y, Mostafavi R. Epidemiology of cutaneous leishmaniasis in Qom province, Iran, during 2003-2009. Qom Univ Med Sci J 2012; 6(1): 83-8. [In Persian].
  15. Jafari R, Mohebali M, Dehghan-Dehnoee A, Soleimani H, Akhavan A, Hajjaran H. Epidemiological status of cutaneous leishmaniasis in Bafgh City, Yazd province 2005. J Shaheed Sadoughi Univ Med Sci 2007; 15(2): 76-83. [In Persian].
  16. Rafati N, Shaporimoghadem A, Ghorbani R. Epidemiological study of cutaneous leishmaniasis in Damghan (2000-2006). Koomesh 2007; 8(4): 247-54. [In Persian].
  17. Turhanoglu M, Alp ES, Bayindir BF. A nine-year evaluation of cutaneous leishmaniasis patients in Diyarbakir Training and Research Hospital, Turkey. Mikrobiyol Bul 2014; 48(2): 335-40.
  18. Uzun S, Durdu M, Culha G, Allahverdiyev AM, Memisoglu HR. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 2004; 90(4): 853-9.
  19. Aytekin S, Ertem M, Yagdiran O, Aytekin N. Clinico-epidemiologic study of cutaneous leishmaniasis in Diyarbakir Turkey. Dermatol Online J 2006; 12(3): 14.
  20. Gurel MS, Ulukanligil M, Ozbilge H. Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997-2000). Int J Dermatol 2002; 41(1): 32-7.
  21. Gontijo CM, da Silva ES, de Fuccio MB, de Sousa MC, Pacheco RS, Dias ES, et al. Epidemiological studies of an outbreak of cutaneous leishmaniasis in the Rio Jequitinhonha Valley, Minas Gerais, Brazil. Acta Trop 2002; 81(2): 143-50.
  22. Hamzavi Y, Sobhi SA, Rezaei M. Epidemiological factors of cutaneous lieshmaniasis in patients reffered to health centers in Kermanshah province (2001 – 2006). Behbood J 2009; 13(2): 151-61. [In Persian].
  23. Tiwary P, Kumar D, Mishra M, Singh RP, Rai M, Sundar S. Seasonal variation in the prevalence of sand flies infected with Leishmania donovani. PLoS One 2013; 8(4): e61370.
  24. Yemisen M, Ulas Y, Celik H, Aksoy N. Epidemiological and clinical characteristics of 7172 patients with cutaneous leishmaniasis in Sanliurfa, between 2001 and 2008. Int J Dermatol 2012; 51(3): 300-4.
  25. Uzun S, Uslular C, Yucel A, Acar MA, Ozpoyraz M, Memisoglu HR. Cutaneous leishmaniasis: evaluation of 3,074 cases in the Cukurova region of Turkey. Br J Dermatol 1999; 140(2): 347-50.
  26. Parvizi P, Akhoundi M, Mirzaei H. Distribution, fauna and seasonal variation of sandflies, simultaneous detection of nuclear internal transcribed spacer ribosomal DNA gene of Leishmania major in Rhombomys opimus and Phlebotomus papatasi, in Natanz district in central part of Iran. Iran Biomed J 2012; 16(2): 113-20.
  27. Ranjbar Totoni A, Soltani AM. Epidemiologic study of cutaneous Leishmaniasis in Noogh/Rafsanjan in 2005. J Kerman Univ Med Sci 2006; 13(2 Suppl): 95. [In Persian].
  28. Ayatollahi J, Karimi M. Cutaneous leishmaniasis prevalence in Abarkuh-Yazd. Iran J Infect Dis Trop Med 2005; 10(30): 13-8. [In Persian].
  29. Kubeyinje EP, Belagavi CS, Jamil YA. Cutaneous leishmaniasis in expatriates in northern Saudi Arabia. East Afr Med J 1997; 74(4): 249-51.
  30. Magill AJ. Leishmania species. In: Bennett J, Dolin R, Blaser MJ, Editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Elsevier Health Sciences; 2010. p. 3463-538.
  31. Soares ME, Pedrosa-Silva AL, Sa E Rocha, Lima NL, Verli FD, Ferreira FO, et al. Epidemiological profile of individuals with American cutaneous leishmaniasis in Jequitinhonha Valley, Brazil. East Mediterr Health J 2014; 19 (Suppl 3): S81-S88.
  32. Jaffary F, Nilforoushzadeh MA, Tavakoli N, Zolfaghari B, Shahbazi F. The efficacy of Achilles millefolium topical gel along with intralesional injection of glucantime in the treatment of acute cutaneous leishmaniasis major. Adv Biomed Res 2014; 3: 111.
  33. Català A, Barnadas MA, Muñoz C, Puig L. Cutaneous Leishmaniasis in a Patient Receiving Infliximab for Psoriatic Arthritis: Treatment with Cryotherapy and Intralesional Meglumine Antimonate. Actas Dermosifiliogr 2014; 105: 714-6.
  34. Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep 2013; 7(2): 31-41.
  35. Croft SL. Monitoring drug resistance in leishmaniasis. Trop Med Int Health 2001; 6(11): 899-905.
  36. Nilfroushzadeh M, Ansari N, Derakhshan R, Siadat AH. Prevalence distribution of resistance to systemic glucantime (meglumine antimony) in the treatment of acute cutaneous leishmaniasis. Journal of Cell and Tissue Research 2008; 8(2): 1379-81.
Journal of Isfahan Medical School
Volume 33, Issue 334 - Serial Number 334
March and April 2015
Pages 676-684

Files

History

  • Receive Date: 03 February 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics